Skip to main content
Indiana University School of Medicine
Indiana University School of Medicine
Department of Medicine
Physician-scientists at IU School of Medicine conduct ground-breaking research studies to understand ulcerative colitis.

Ulcerative Colitis Research Studies

Ulcerative colitis (UC) is an inflammatory bowel disease. It causes irritation, inflammation, and ulcers in the lining of the large intestine.

Investigators

5139-Bohm, Matthew

Matthew Bohm, BA, DO

Associate Professor of Clinical Medicine

Read Bio Matthew Bohm, BA, DO

4964-Fischer, Monika

Monika Fischer, MD

Professor of Medicine

Read Bio Monika Fischer, MD

5125-Sagi, Sashi

Sashi Sagi, MD

Associate Professor of Clinical Medicine

Read Bio Sashi Sagi, MD

Open Research Studies for Ulcerative Colitis

SPARC IBD

Enrolling: Yes

Principle Investigator: Matthew Bohm, DO

Duration:  All bio-specimen collections and chart reviews will continue until 2026

Patient Population: Any patient with either Crohn’s Disease or Ulcerative Colitis

Study Intervention:  Medical chart reviews and biological specimen collection.

Interested in this study? Please contact the IBD research team: iuibd@iu.edu

FibroScan® Study

Enrolling: Yes

Principle Investigator: Sashidhar Sagi, MD

Duration: One time scan (1 in person visit)

Patient Population: Adult patients with Crohn's Disease or Ulcerative Colitis fasting for 2 hours prior.

Interested in this study? Please contact our IBD research team: iuibd@iu.edu

IBD QORUS

Enrolling: Yes

Principle Investigator: Sashidhar Sagi, MD

Duration: Indefinite or upon withdraw

Patient Population: Any patient with either Crohn’s Disease or Ulcerative Colitis

Study Procedures: Patient surveys before every office visit & medical chart reviews

Interested in this study? Please contact the IBD research team: iuibd@iu.edu

Janssen DUET-UC

Enrolling: Yes

Principle Investigator: Sashidhar Sagi, MD

Duration: 5 years (visits every 4 weeks)

Patient Population: Adult patients with moderate to severe UC with failure to at least 1 approved therapy.

Drug(s): Guselkumab, Golimumab, or the co-formulation (9% change of placebo)

Interested in this study? Please contact our IBD research team: iuibd@iu.edu

Closed Ulcerative Colitis Studies

  • TOUR

    Principle Investigator:  Monika Fischer, MD

    Duration:  12 months

    Patient Population: Any patient with Ulcerative Colitis starting Tofacitinib (Xeljanz) for the first time as part of their standard treatment for UC.

    Study Intervention:  Medical chart review and e-mail patient questionnaires (Enrollment and participation is done via phone.)